2026/04/01 by Alison Beck, Briony Larance, Bradley Wakefield +7 · 1 voice
Medicine · #Telemedicine and Telehealth Implementation #Opioid Use Disorder Treatment #Substance Abuse Treatment and Outcomes
paper · doi:10.1111/acer.70298
openalex publication_date 2026/04/01 · openalex created_date 2026/04/12 · openalex updated_date 2026/08/01
BACKGROUND: The COVID-19 pandemic disrupted face-to-face alcohol and other drug (AOD) treatment services and prompted greater use of telehealth. This study measured the impact of COVID-19 on outpatient treatment episodes before, during, and after stay-at-home orders were introduced. METHODS: This observational study used routinely collected data from community-based non-government AOD services in New South Wales (NSW), Australia across 4 years (209 7-day intervals from January 1, 2019-January 2, 2023). Interrupted time-series analyses with seasonal autoregressive integrated moving average (ARIMA) modeling estimated weekly changes in outpatient treatment episodes associated with stay-at-home (lockdown) orders, including (1) commencements, (2) planned cessations, and (3) unplanned cessations. Episode counts were also examined by gender (male, female), age group (< 25 years, 25-59 years, ≥ 60 years), principal drug of concern (alcohol, amphetamines, cannabinoids, opioids, and other), and location (metropolitan and non-metropolitan). RESULTS: There were no significant level or trend changes in the overall number of episode commencements (ARIMA (2,0,0)(1,0,0), lockdown one: βlevel = -814.85, p = 0.098; βslope = 11.14, p = 0.127; lockdown two: βlevel = 317.3, p = 0.427; βslope = -3.47, p = 0.237), planned cessations (ARIMA (1,0,0)(0,0,1), lockdown one: βlevel = -142.1, p = 0.66; βslope = 1.16, p = 0.808; lockdown two: βlevel = -199.07, p = 0.432; βslope = 0.18, p = 0.932), or unplanned cessations (ARIMA (1,0,0), lockdown one: βlevel = -92.4, p = 0.717; βslope = 1.4, p = 0.711; lockdown two: βlevel = -121.19, p = 0.563; βslope = 0.53, p = 0.732) in outpatient non-government AOD services at either lockdown. For subgroups, during lockdown one, commencements per week increased for metropolitan participants (ARIMA (1,0,0) βlevel = -725.12, p = 0.024; βslope = 10.07, p = 0.035) and those with amphetamines (ARIMA(3,0,0)(1,0,0) βlevel = -338.44, p = 0.036; βslope = 4.68, p = 0.05) as their principal drug of concern. CONCLUSIONS: The introduction of COVID-19 lockdown measures did not appear to adversely impact the number of NSW non-government AOD outpatient treatment episodes delivered nor the likelihood of unplanned dropout. Our findings illustrate the likely role of telehealth in sustaining (and for some groups, perhaps temporarily increasing) AOD service provision during the COVID-19 pandemic. This highlights the sector's resilience in sustaining care under challenging circumstances.